TREMFYA, the first and only selective interleukin (IL)-23 inhibitor therapy approved in the U.S. to treat both adults with active PsA and adults with moderate to severe plaque psoriasis (PsO), demonstrated low rates of structural damage progression and durable improvements in physical function at week 100 Approximately 80-90 percent of TREMFYA-treated patients who achieved improvements in joint signs and symptoms and low levels of disease activity at week 52 (ACR20/50 and MDA) maintained this response at week 100
